Shengtai Pharmaceutical Hosts Key Customers at Its Headquarters for Facility Tour and Technology Exchange Conference
WEIFANG,
Pharmaceutical, Inc. (OTC Bulletin Board: SGTI) (“Shengtai” or “the Company”),
a leading manufacturer and distributor of high-quality, pharmaceutical grade
glucose products in
Company’s headquarters to showcase its new
state-of-the-art 120,000-ton glucose production facility as well as conducted
high-level discussions with key existing customers.
Representatives and officials from over 70 current customers were on hand
for the three-day event. Mr. Qingtai Liu, Chairman of Shengtai and other
senior members of the Company spoke during the conference as they presented
their view on the current operating environment, status of the glucose
production facility, as well as high level discussions on strategies that can
help the Company to continue to deliver on its promise to provide the highest
quality products to end customers. The three-day conference also offered the
guests with an opportunity to visit the on-site production facilities. The
event provided the Company management with valuable information on customers’
expectations and motivations, and strategic insights into what the Company
needs to do to further business development and cooperation with its key
customers. Many of whom attended the conference congratulated the Company for
consistently delivering high quality products. They also stated they look
forward to continuing to work closely with the Company as it is on its way to
becoming the top domestic supplier of pharmaceutical grade glucose.
“The activities of this past week not only gave us an opportunity to
showcase our state-of-the-art production facilities, our customers were able
to gain a better understanding of our operations, production capabilities, and
quality control as we develop deeper and more meaningful relationship with
many of our key customers,” said Mr. Qingtai Liu, CEO of Shengtai
Pharmaceutical, Inc. “In order to compete more effectively in these
challenging times, we must continue to show improvement in terms of product
development as well as optimize customers overall experience. As one of the
leading domestic producers of pharmaceutical grade glucose, we have a
responsibility to produce the highest quality products. Our critical
health-related products have achieved global quality standards, and our
strategic location gives us cost advantage which will benefit our customers by
using our products. As we look ahead, the Company is poised to be one of the
major beneficiaries from the changing healthcare landscape as a result of the
planned government reform.”
About Shengtai Pharmaceutical, Inc.
Shengtai Pharmaceutical, Inc. through its wholly owned subsidiary,
Shengtai Holding, Inc. (SHI), and the Chinese operating company of Weifang
Shengtai Pharmaceutical Co., Ltd., is a leading manufacturer and supplier of
pharmaceutical grade glucose used for medical purposes. It also manufactures
and supplies glucose and cornstarch products to the food, beverage and
industrial production industries in
Forward-looking Statements
Certain statements made in this news release, may contain forward-looking
statements concerning the Company’s business and products. These statements
include, without limitation, statements regarding our ability to prepare the
Company for growth, future increases in market demand, possible increases in
our market share and predictions and guidance relating to the Company’s future
financial performance. We have based these forward-looking statements largely
on our current expectations and projections about future events and financial
trends that we believe may affect our financial condition, results of
operations, business strategy and financial needs, but they involve risks and
uncertainties that could cause actual results to differ materially from those
in the forward-looking statements, which may include, but are not limited to,
such factors as unanticipated changes in product demand especially in the
pharmaceutical industry, pricing and demand trends for the Company’s products,
changes to government regulations, risk associated with operation of the
Company’s new facilities, risk associated with large-scale implementation of
the Company’s business plan, the ability to attract new customers, ability to
increase our products’ applications, cost of raw materials, downturns in the
Chinese and world economy, and other information detailed from time to time in
the Company’s filings and future filings with the United States Securities and
Exchange Commission. Investors are urged to consider these factors carefully
in evaluating the forward-looking statements herein and are cautioned not to
place undue reliance on such forward-looking statements, which are qualified
in their entirety by this cautionary statement. The forward-looking statements
made herein speak only as of the date of this press release and the Company
undertakes no duty to update any forward-looking statement to conform the
statement to actual results or changes in the Company’s expectations.
For more information, please contact:
Shengtai Pharmaceutical, Inc.
Ms. Yiru Melody Shi
Chief Financial Officer
Email: shengtaicfo@hotmail.com
Grayling
Eddie Cheung
Investor Relations
Tel: +1-646-284-9414
Email: eddie.cheung@us.grayling.com
SOURCE Shengtai Pharmaceutical, Inc.